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Abstract
Background and Purpose: Patients with severe, progressive multiple sclerosis (MS) have complex physical
and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay
further clinical worsening in this population. The objective was to develop an evidence-based clinical practice
guideline for the palliative care of patients with severe, progressive MS.
Methods: This guideline was developed using the Grading of Recommendations Assessment, Development and
Evaluation methodology. Formulation of the clinical questions was performed in the Patients–Intervention–
Comparator–Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of
severe MS exists: in this guideline, constant bilateral support required to walk 20 m without resting (Expanded
Disability Status Scale score >6.0) or higher disability is referred to. When evidence was lacking for this population,
recommendations were formulated using indirect evidence or good practice statements were devised.
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Results: Ten clinical questions were formulated. They encompassed general and specialist palliative care,
advance care planning, discussing with HPs the patient’s wish to hasten death, symptom management, multi-
disciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommenda-
tions (33 weak, 1 strong) and seven good practice statements were devised.
Conclusions: The provision of home-based palliative care (either general or specialist) is recommended with
weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and
MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning,
the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs.
Keywords: clinical practice guideline; GRADE assessment; multiple sclerosis; palliative care
Introduction
Multiple sclerosis (MS) is a chronic neurologicaldisease affecting 2.3 million people worldwide. It has a
variety of clinical presentations, an unpredictable disease
course, and is the most common cause of neurological dis-
ability in young adults in many western countries.1 Around
15% of MS patients have a progressive course from the outset
(primary progressive MS); a further 40% develop progres-
sive disease after 15 years with relapsing–remitting disease
(secondary progressive MS).2 No uniform definition of se-
vere MS exists: in this guideline, patients needing constant
bilateral support (cane, crutch or braces) to walk 20 m with-
out resting [i.e. Expanded Disability Status Scale (EDSS)
score >6.0]3 or higher disability are referred to. A significant
proportion of such patients need assistive devices4 and they
are at risk of death from aspiration pneumonia, urinary tract
infections, complications of falls and fractures, and sepsis
secondary to pressure ulcers.5,6 Nevertheless, some patients
with severe, progressive MS (hereafter, severe MS) live for
many years, and most die in hospital rather than at home.7,8
The provision of palliative care (PC) has been proposed to
help respond to the complex and varying bio-psychosocial
needs of patients with severe MS, for whom few treatment
options are currently available to delay or prevent further
clinical worsening.9–12
Scope
This guideline was devised by an international task force
(TF) appointed by the European Academy of Neurology
(EAN) in partnership with the European Association for
PC (EAPC) and the European Network for Best Practice and
Research in MS Rehabilitation (RIMS). TF members were
also appointed by the MS International Federation (MSIF)
and by the European Committee for Treatment and Research
in MS (ECTRIMS). This collaborative, multiple stakeholder
approach was adopted to reflect practice across a variety of
healthcare systems in Europe.
The aim was to focus on outcomes that are important for pa-
tients and useful for caregivers and healthcare professionals
(HPs). To ensure this, the clinical questions were formulated via
direct engagement of MS patients and caregivers.13 The primary
intended audience is clinicians working in MS care, PC, emer-
gency medicine, nursing, rehabilitation and related disciplines.
In addition, policy-makers, charities and other stakeholders may
find this guideline useful for informing and planning policies.
A pertinent document to the guideline is the EAN con-
sensus review on PC for patients with chronic and progres-
sive neurological diseases.10
Methods
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) methodology and the
updated EAN recommendations were followed.14 A TF of
21 members from nine European countries and three disci-
plines (neurology, PC, rehabilitation) was assembled, with
invitations from the chair (AS) on the basis of expertise in
MS care. JD, IM, RM, RV and DO were appointed by the
EAN; SV, RV and DO by the EAPC; MAB, JD and JSG by
the RIMS, and JSG and RV by the ECTRIMS (Appendix S1).
The clinical questions
Ten clinical questions were formulated by the TF in Patients–
Intervention–Comparator–Outcome (PICO) format (Appendix
S2). The formulation was guided by literature search, MS expert
survey (47 participants), MS patients and caregivers online
survey (1119 participants) and five focus group meetings (three
of MS patients, two of caregivers; overall 35 participants). The
TF, originally organized into a Guideline Working Panel and a
Methodological Panel, added a Client Consultation Panel to
help with this phase, which took place between April 2017 and
February 2018 and is detailed in a dedicated paper.13 In October
2018, TF members independently rated the importance of the
outcomes identified for each clinical question on a 9-point
scale15 (Fig. 1): all outcomes were considered as critical (score
range 7–9) or important but not critical (score range 4–6).
Literature search
Seven electronic databases were searched from inception to
October 2018: MEDLINE (OVID), PubMed, Embase, Psy-
cINFO, CINAHL, Cochrane Central Register of Controlled
Trials and Cochrane Database of Systematic Reviews. The
search strategies were developed in collaboration with two in-
formation specialists. The full MEDLINE search strategies are
provided in Appendix S3. The search was expanded by looking
at the references in the studies selected and at citations in the
Web of Science Citation Index; by hand search of the online
material available for major PC and MS journals; and by search
on clinical trials registries and guideline (www.guidelines.gov)
and health technology assessment (www.inahta.org) websites.
Study selection and data extraction
Between July and December 2018, two TF members in-
dependently reviewed the titles and abstracts identified and
discarded the clearly irrelevant ones and those that did not
meet the inclusion criteria. Any discrepancy at this stage was
resolved by consensus. Full text of the selected studies was
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then reviewed independently by the two reviewers. Any
disagreement regarding inclusion of individual studies was
resolved by consensus; if agreement was not obtained, the
full-text study was sent to a third independent reviewer for
adjudication. Full details of the literature selection results
for each clinical question are presented in Appendix S4.
Data from each included study were extracted by one TF
member using an electronic form. A second member checked
the data and disagreement was resolved by consensus; if
consensus was not obtained, a third TF member was invol-
ved. Two TF members assessed the quality of evidence of
the included studies using the Cochrane tool for risk of
bias (randomized controlled trials, RCTs)16 and the CASP
10-item tool (qualitative studies, http://www.casp-uk.net/
#!casp-tools-checklists/c18f8). Any disagreement was re-
solved by consensus; if consensus was not obtained, a third
TF member was involved.
Data synthesis
For general and specialist PC (clinical questions 1 and 2),
an individual participant data meta-analysis (IPDMA)17 was
used to estimate the overall effect of the three RCTs currently
available,18–20 one of which enrolled a mixed population of
participants with neurodegenerative disorders, including MS
(18/ 49, 37%).19 The baseline scores (T0) and the end-of-
study scores (T1, at 12 weeks for the UK,18 16 weeks for the
NE-PAL trial19 and 24 weeks for the PeNSAMI trial20) were
considered. Domains that were assessed by all the studies
were identified. For each domain, multivariate linear re-
gression models were used to estimate the variability of
the weighted score difference between PC and usual care
groups, controlling for study, baseline EDSS score and
baseline domain score. The one-stage approach was selected
as it provides a more exact likelihood in the case of small
studies.21 Our primary IPDMA analysis was intention-to-
treat, with multiple imputations of the missing data via
logistic regression models.22 A per-protocol analysis was
also performed. Further, a sensitivity analysis was performed
after exclusion of the PeNSAMI trial,20 to check whether
the results obtained from all three studies (clinical questions
1 and 2) were consistent with those of the two studies on
specialist PC (clinical question 2).
It was not possible to perform a quantitative synthesis on
the other clinical questions, except for nabiximols for spas-
ticity (clinical question 5) where a random-effects model
meta-analysis was used. The effect on spasticity (patient-
reported numerical rating scale, NRS) and caregiver-reported
global impression of change (CGIC) scores were considered
as they were used in all three included studies.23–25 The mean
NRS differences between end of study and baseline reported
in each study and, for CGIC, the odds ratios of nabiximols
versus placebo were estimated. Between-study heterogeneity
was assessed by Higgins I2 statistic with 95% confidence
intervals (CIs). The meta-analyses were performed by an
independent statistician (MC) and an EAN methodologist
(KA). The preliminary and final results of the IPDMA were
shared with the authors of the included studies. The IPDMAs
were performed using STATA 16 (STATA College Station,
TX, USA) and meta-analyses using RevMan 5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen,
Denmark).
FIG. 1. Outcomes identified as important (score range 4–6; blue bars) or critical (score range 7–9; red bars) by the task
force for each clinical question on a 9-point scale.15 ADL, activities of daily living; HP, healthcare professional;
MS, multiple sclerosis; QOL, quality of life; SDM, shared decision-making.
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Formulation of recommendations
Two TF members from the methodological panel formu-
lated the preliminary wording and grading for each recom-
mendation. Agreement upon the direction (‘for’ or ‘against’)
and the strength (‘strong’ or ‘weak’) of each recommendation
was obtained via teleconferences and electronic discussions,
using a modified Delphi method.26 Agreement was reached
after one clinical round for recommendations pertaining to
clinical questions 7–10, after two rounds for recommendations
pertaining to clinical questions 1–4 and 6, and after two to three
rounds for recommendations pertaining to clinical question 5.
Ethics statement
The guideline protocol was approved by the ethics com-
mittee of the Fondazione IRCCS Istituto Neurologico Carlo
Besta, Milan, Italy (ref. no. 34, 2016).
Results
General and specialist palliative care (clinical
questions 1 and 2)
PC seeks to improve the quality of life of patients and their
families facing a life-threatening illness, through the pre-
vention and relief of suffering by means of early identifica-
tion and impeccable assessment and treatment of pain and
other problems, physical, psychosocial and spiritual.27 The
PC provided by HPs who specialize in this discipline is
known as specialist PC. Special PC services are characterized
by a multiprofessional team approach and interdisciplinary
mode of work.28 General PC can be provided by primary and
specialist HPs who have attained PC competences but do not
provide PC as the main focus of their work.
Ten publications on PC interventions were found: two de-
scribed a qualitative study assessing the experiences of nine
MS patients participating in a PC daycare programme29,30 and
eight described three RCTs.18–20,31–35 The characteristics of
the RCTs, and participants, are reported in Table 1.
The UK trial18,32,33 and NE-PAL19 were single-centre
RCTs comparing home-based specialist PC to usual care (1:1
ratio). PeNSAMI20,34 was a multicentre RCT comparing
home-based general PC to usual care (2:1 ratio). The inter-
vention lasted 12 weeks in the UK trial, 16 weeks in the NE-
PAL trial and 24 weeks (with a 12-week assessment) in the
PeNSAMI study. The risk of bias was low overall except for
performance bias (all studies) and detection bias (UK and
NE-PAL). UK trial participants were slightly younger (mean
age 53 years), less severely affected (median EDSS 7.5) and
predominantly women (68%) compared to participants in the
other two studies (Table 1). Each patient had a caregiver who
participated in the trial (in most instances a woman, and
patient spouse or partner).
Eight domains were assessed by all the studies (Table 2):
pain, shortness of breath, bladder problems, bowel problems,
anxiety, depression, sleeping problems and caregiver burden.
Figure 2 illustrates the mean changes in these domains by
study arm across the three studies.
Individual participant data meta-analysis results are re-
ported in Fig. 3 and Table 3, which provide data for the
intention-to-treat and per-protocol analyses considering both
the full dataset and the sensitivity analyses. Besides the in-
tervention, in each regression model two covariates were
retained: the study and the baseline domain score (results
with the baseline EDSS score included were similar; data
not shown). A statistically significant effect in favour of
PC was found on pain (regression coefficient —17.36; 95%
CI —31.54 to —3.18) and sleeping problems (regression
coefficient —14.15; 95% CI —26.93 to —1.36), whilst there
was no effect on the remaining five symptoms and on care-
giver burden (Fig. 3; Table 3).
The per-protocol analysis was consistent with intention-to-
treat findings except for a significant reduction in caregiver
burden (mean coefficient —7.07; 95% CI —12.88 to —1.26)
in the sensitivity analysis.
In conclusion, three RCTs reporting on the effectiveness of
PC services compared to usual care were found. Two studies
assessed home-based specialist PC18,19 and one study home-
based general PC.20 Studies differed in length of follow-up
(12–24 weeks) but were considered sufficiently homogene-
ous for a quantitative synthesis. Overall, there is low certainty
in our findings, mostly due to risk of bias and imprecision.
Also, publication bias cannot be ruled out.
A statistically significant effect in favour of PC was found
for two of the eight domains considered, pain and sleep-
ing problems. A per-protocol analysis additionally found a
reduction in caregiver burden, for specialist PC only. There
is no evidence of effects on quality of life and on the
other outcomes. No studies were found on inpatient or out-
patient PC.
Recommendation. It is suggested that home-based PC
is offered to patients with severe MS, either by HPs with good
basic PC skills and knowledge (general PC) or by multi-
professional teams of PC specialists (specialist PC) (weak
recommendation, low certainty evidence).
Good practice statement. It is suggested that inpatient
or outpatient PC is offered to patients with severe MS. Patient
preference, living conditions and availability of PC services
should be taken into account.
Recommendations pertaining to clinical questions 3–10
are reported below. A full report which also contains the
references of the included studies for these questions is
available in Appendix S5.
Advance care planning (clinical question 3)
According to the EAPC, advance care planning (ACP) is a
process that enables individuals who have decisional capacity
to identify their values, to reflect upon the meanings and
consequences of serious illness scenarios, to define goals and
preferences for future medical treatment and care, and to
discuss these with family and HPs. ACP addresses individ-
uals’ concerns across the physical, psychological, social, and
spiritual domains. It encourages individuals to identify a
personal representative and to record and regularly review
any preferences, so that their preferences can be taken into
account should they, at some point, be unable to make their
own decisions.36
Of 617 records screened, seven were assessed as full text
and excluded from the final selection (Appendix S5). From a
systematic review,37 there is no evidence of the effects of
ACP for people with neurological diseases, including MS.
However, there is some evidence from other progressive










































































































































































































































































































































































































































































































































































































































































































































































































































































and life-threatening illnesses that ACP decreases the use of
life-sustaining treatment, increases hospice/PC, reduces
hospitalizations and increases compliance with patients’ end-
of-life wishes.37
Concerning MS, there is evidence that patients and care-
givers often would like to discuss the issues of death and
dying and HPs should acknowledge and encourage these
discussions.38,39 Often professionals leave discussions until
the later stages of progression in MS.40 Patients react in
different ways on discussion of future planning: a small study
showed that some MS patients made clear decisions, some
undertake some planning but without a clear advance direc-
tive and some were still ‘hoping for a cure’ and did not wish
to look ahead.41 However, caregivers may be left having











et al., 2017,19 Solari
et al., 201820)
Of seven symptoms assessed by all three RCTs using
different measures (MS-POS-5S, Core-POS,
POS-S-MS, POS-8, VAS) there was a significant
improvement in the PC group but not in the UC group
over follow-up for pain and sleeping problems, whilst
there was no difference between groups for shortness








2017,19 Solari et al.,
201820)
SEIQOL-DW was used in both RCTs. No differences
were found on mean change in SEIQOL-DW total
score over 16/24 weeks between the PC group and the








2017,19 Solari et al.,
201820)
In Veronese et al.19 there was one unplanned
hospitalization (UC group) versus none in the PC
group over 16 weeks. In Solari et al.20 there were
12 (24%) unplanned hospitalizations in the PC group










et al., 2017,19 Solari
et al., 201820)
There were five deaths overall: two in Edmonds et al.,
201018 (one in the PC group, at the patient’s home; one
in the UC group, place not specified); none in
Veronese et al., 201719; three in Solari et al., 201820











Not reported Not reported Statistically significant mean
total cost saving per patient over 12 weeks of £1789
for PC versus UC (including inpatient and informal
caregiver savings). No statistical differences were
found for PC (versus UC) in community costs per
patient and in costs to informal caregivers; the saving
appeared to be mainly due to a lower use of primary





Caregiver quality of life
(Solari et al., 201820)
There was no effect of PC (versus UC) on both SF-36






There was no effect of PC (versus UC) on both HADS








et al., 2017,19 Solari
et al., 201820)
The three studies used different measures (CBI, ZBI-12,
ZBI-22) and there was no effect of PC (versus UC)
in the combined analysis (P= 0.46). For specialist PC
data (2 RCTs), there was a reduction in caregiver







Patient or population: patients with severe multiple sclerosis. Setting: home-based patient care. Intervention: palliative care (PC).
Comparison: usual care (UC). GRADE Working Group grades of evidence. High certainty: there is great confidence that the true effect lies
close to that of the estimate of the effect. Moderate certainty: there is moderate confidence in the effect estimate; the true effect is likely to be
close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate
is limited; the true effect may be substantially different from the estimate of the effect. Very low certainty: there is very little confidence in the
effect estimate; the true effect is likely to be substantially different from the estimate of the effect. CBI, Caregiver Burden Index; Core-POS,
Core Palliative Outcome Scale; HADS, Hospital Anxiety and Depression Scale; ITT, intention to treat; MCS, Mental Composite Scale; MS-
POS-5S, Multiple Sclerosis Palliative Outcome Scale 5 Symptoms; PCS, Physical Composite Scale; POS-8, Eight-item Palliative outcome
Scale; POS-S-MS, Palliative Outcome Scale Symptoms Multiple Sclerosis; RCT, randomized controlled trial; SEIQOL-DW, Schedule for the
Evaluation of Individual Quality of Life Direct Weight; SF-36, 36-item Short Form Health Survey; VAS, Visual Analogue Scale; ZBI-12, 12-
item Zarit Burden Index; ZBI-22, 22-item Zarit Burden Index. aVery serious risk of bias. bSerious risk of bias. cImprecision.
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difficult decisions if no planning has taken place and this is
stressful for caregivers.42
Good practice statements.
1. It is suggested that early discussion of the future with
ACP is offered to patients with severe MS.
2. It is suggested that regular communication about the
future progression of MS is undertaken with patients
and families/caregivers.
Patient discussion with HPs of their wish
to hasten death (clinical question 4)
Healthcare professionals’ acknowledgment of, and open
discussion about, the patient’s wish to hasten death and re-
lated issues emerged as key from both TF members (chiefly
PC physicians) and MS patients.13 Of 491 records screened,
seven were assessed as full text and excluded from the final
selection (Appendix S5). Berkman et al.43 reported that 33%
of MS patients considered suicide or assisted dying. In
more recent studies, 22% of MS patients had suicidal in-
tention,44 and 7% would consider suicide and 65% assisted
dying if they had unbearable pain.45 Suicidal ideation or
consideration of assisted dying was related to depression,
hopelessness, MS affecting leisure time and feeling socially
isolated.11,46 Access to PC expertise has been recommended
for individuals requesting euthanasia or physician-assisted
suicide as further assessment and management of symptoms,
psychosocial or spiritual distress.47
Good practice statements.
1. Patients should be encouraged to discuss their wishes
about future care, including the restriction of treatment
and interventions and the wish for hastened death.
2. Healthcare professionals should be aware of the risk
factors for the wish for hastened death – including
depression, isolation, restricted abilities – and encour-
age the discussion of these issues and the appropriate
management.
Symptom management (clinical question 5)
This patient population is characterized by the presence
of multiple symptoms, in variable combinations between
patients and in the same patient over time (Table 4). The
management of pain and other symptoms is at the core of
PC. Nevertheless, some symptoms (e.g. spasticity, fatigue)
typically affect MS patients and were not addressed in clin-
ical questions 1 and 2. Patients with severe MS should be
carefully and regularly assessed in order to proactively detect
their bio-psychosocial symptoms. Whenever necessary (e.g.
in patients with severe cognitive compromise or communi-
cation problems), interviews with patient caregivers and the
use of proxy versions of symptom scales should be added
to patient assessment.
Of 7195 records screened, 530 were assessed as full text
and 44 (43 trials) were included. Ten publications addressed
more than one symptom. The symptom with the highest
FIG. 2. Boxplots of the 0/100 transformed score changes in each of the eight domains, by arm and across the three studies
(per-protocol data). The top and bottom of each box are the 25th and 75th percentiles; the horizontal line inside the box is
the median; the whiskers are the upper and lower adjacent values; the dots are outlier values.
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number of publications was spasticity, followed by fatigue
and pain (Table 4).
Considering the type of intervention, 32/43 trials (75%)
were on pharmacological interventions, 10 (23%) on non-
pharmacological approaches and one (2%) was a trial
assessing a combination of botulinum toxin A and physio-
therapy. No studies on interventions targeted to the man-
agement of 10/19 pre-specified symptoms were found in
our literature search (Table 4). Further, the included studies
reported on few of our predefined outcomes. Recommen-
dations on four symptoms (spasticity, fatigue, pain and
bladder problems) were produced. For each symptom, a full
report is available in Appendix S5 and summary of findings
tables in Appendix S6.
Spasticity
The majority of the included publications (32/44, 73%;
31 trials) addressed spasticity as an outcome. Of these, 26
trials (84%) addressed drugs (baclofen, benzodiazepines,
cannabinoids, GABAergics, tizanidine and botulinum tox-
in) and five trials addressed nonpharmacological treatments
(exercise, radial shock wave therapy and transcutaneous
electrical nerve stimulation). A meta-analysis was per-
formed for nabiximols: all the three RCTs23–25 shared the
patient-reported NRS for spasticity and CGIC ‘ease of
transfer’ (Table 5). Mean NRS spasticity difference fa-
voured nabiximols (—0.51; 95% CI —0.96 to —0.07); and
the odds ratio for CGIC ‘ease of transfer’ improvement was
1.99 (95% CI 1.17–3.38) for nabiximols versus placebo
(Fig. 4).
Recommendations.
1. Nabiximols are recommended to reduce spastic-
ity in patients with severe MS. Drug availability,
the presence of other symptoms and possible ad-
verse events should be considered in treatment
FIG. 3. Individual participant data meta-analysis results. Intention-to-treat results are reported in black, and per-protocol
results are reported in grey. In each model the dependent variable is the 0/100 transformed score change on the domain;
the independent variables are the intervention, the study and the 0/100 transformed baseline score. PC, palliative care;
UC, usual care.







2. Oral baclofen is suggested to reduce spasticity in
patients with severe MS (weak recommendation/
very low certainty evidence). Presence of other
symptoms and possible adverse events should be
considered in treatment decision-making.
3. Intrathecal baclofen is suggested to reduce spasticity
in patients with severe MS (weak recommendation/
very low certainty evidence). The presence of other
symptoms and possible adverse events (related to
the drug and to pump and catheter placement/
replacement) should be considered in treatment
decision-making.
4. Tizanidine is suggested to reduce spasticity in pa-
tients with severe MS (weak recommendation/ low
certainty evidence). The presence of other symptoms
and possible adverse events should be considered in
treatment decision-making.
5. GABAergic drugs are suggested to reduce spasticity
in patients with severe MS (weak recommendation/
low or very low certainty evidence). The presence of
other symptoms and possible adverse events should
be considered in treatment decisionmaking.
6. Other cannabinoids (D9-tetrahydrocannabinol
or cannabis sativa plant extract) are suggested to
reduce spasticity in patients with severe MS (weak
recommendation/moderate certainty evidence). Drug
availability, the presence of other symptoms and
possible adverse events should be considered in
treatment decision-making.
7. Botulinum toxin A is suggested to reduce hip adductor
spasticity in patients with severe MS (weak recom-
mendation/low certainty evidence). The presence of
other symptoms and possible adverse events should be
considered in treatment decision-making.
8. Exercise is suggested to reduce spasticity in patients
with severe MS (weak recommendation/ very low
certainty evidence), considering patient preferences
and resource availability.
Table 3. Individual Participant Data Meta-Analysis Results,
with Data Adjusted for Study and Baseline Score
Domain
Full dataset (clinical questions 1 and 2) Sensitivity analysis (clinical question 2)
Coefficient SE P value 95% CI Coefficient SE P value 95% CI
Intention to treat
Pain 9.81 4.52 0.032 -18.76 to -0.85 -17.36 7.09 0.017 -31.54 to -3.18
Shortness of breath -2.57 3.67 0.485 -9.83 to 4.69 -6.41 4.89 0.195 -16.20 to 3.37
Bladder problems 8.11 4.16 0.054 -0.15 to 16.37 11.06 6.84 0.111 -2.62 to 24.74
Bowel problems -1.52 5.12 0.768 -11.65 to 8.62 10.39 7.06 0.146 -3.73 to 24.51
Anxiety -9.38 5.19 0.073 -19.65 to 0.88 -9.56 8.22 0.249 -26.03 to 6.90
Depression 1.54 3.99 0.700 -6.37 to 9.44 -1.74 6.79 0.798 -15.38 to 11.89
Sleeping problems -9.88 4.01 0.015 -17.81 to -1.94 -14.15 6.39 0.031 -26.93 to -1.36
Caregiver burden -2.61 3.53 0.465 -9.78 to 4.56 -5.80 5.76 0.325 -17.72 to 6.12
Service satisfactiona 9.81 9.50 0.307 -9.26 to 28.88
Per protocol
Pain -8.98 4.49 0.048 -17.87 to -0.10 -16.83 7.03 0.020 -30.89 to -2.77
Shortness of breath -3.00 3.70 0.420 -10.31 to 4.32 -6.94 4.97 0.168 -16.89 to 3.01
Bladder problems -1.94 5.49 0.724 -12.81 to 8.93 11.09 7.96 0.170 -4.89 to 27.06
Bowel problems -9.50 5.20 0.070 -19.79 to 0.79 -10.02 8.24 0.229 -26.50 to 6.47
Anxiety 7.42 4.30 0.087 -1.11 to 15.95 8.39 7.26 0.253 -6.17 to 22.95
Depression 1.57 4.01 0.697 -6.37 to 9.52 1.61 6.72 0.811 -15.09 to 11.86
Sleeping problems -8.22 3.90 0.037 -15.92 to -0.51 -10.50 6.16 0.093 -22.82 to 1.82
Caregiver burden -1.92 1.91 0.318 -5.72 to 1.87 -7.07 2.84 0.019 -12.88 to -1.26
Service satisfactiona 13.68 9.92 0.174 -6.22 to 33.59
Statistically significant values are reported in bold; CI, confidence interval. aNot assessed in the PeNSAMI study.
Table 4. Publications Found for Each Specified
Symptom (10 Out of 43 Trials Addressed




Spasticity 32 31 1975–2017
Fatigue 10 9 2001–2017
Paina 7 6 2003–2017
Sleeping problemsa 6 5 2003–2017
Bladder problemsa 6 4 1996–2006
Mobility/transfer 5 5 1996–2017
Tremor 4 3 2003–2009
Balance 1 1 2015








Depressed mooda 0 – –
Cognitive problems 0 – –








Mouth problems 0 – –
aAlso addressed in clinical questions 1 and 2 (general and
specialist palliative care).
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(Collin et al., 2010,23 Novotna
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201225)
The meta-analysis showed a significant difference
between groups for spasticity NRS (mean






Symptom burden (MAS) (Collin
et al., 2010,23 Novotna et al.,
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There were no significant differences between
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ADL (Collin et al., 2010,23
Novotna et al., 201124)
There was a significant difference between groups
in Novotna et al. favouring nabiximols, but not





QOL (Collin et al., 2010,23
Novotna et al., 201124)
There was no difference between groups in Collin






CGIC (ease of transfer, meta-
analysis) (Collin et al., 2010,23
Novotna et al., 2011,24
Notcutt et al., 201225)
The meta-analysis of CGIC showed a significant






Adverse events (Collin et al.,
2010,23 Novotna et al.,
2011,24 Notcutt et al., 201225)
Collin et al.: A total of 55 patients (16%)
discontinued treatment early; 35 (21%) in the
nabiximols group and 20 (12%) in the placebo
group. Of these 55 patients, 32 (58%) withdrew
from the study. The primary reason given for
withdrawal was AE occurrence: nine patients
(5%) on nabiximols and five (3%) on placebo.
The following AEs were reported more frequently
in the nabiximols group compared to placebo:
dizziness [53/167 (32%) vs. 17/170 (10%)],
fatigue [42/167 (25%) vs. 32/170 (19%)],
somnolence [24/167 (14%) vs. 7/170 (4%)],
nausea [53/ 167 (32%) vs. 17/170 (10%)],
asthenia [26/167 (16%) vs. 11/170 (6%)] and
vertigo [19/167 (11%) vs. 7/170 (4%)]. Two
subjects died from cancer during the study: neither
death was considered to be related to the (active)
study medication Notcutt et al.: There was one
SAE (pain in hip and thigh and lumbar spinal
stenosis) in a patient on nabiximols, which was
considered unrelated to study medication. The
only AE reported in association with abnormal
laboratory values was a mild increase in gamma-
glutamyl transferase in one patient on nabiximols.
Novotna et al.: 17 patients discontinued the
treatment early (7%); 15 were on nabiximols (four
due to AEs, 11 due to withdrawal of consent).
AEs were overall few and similar between
nabiximols and placebo, with no single event
occurring at a rate >10% in either group; the most
common AEs were vertigo (6% nabiximols vs.






Patient or population: people with severe multiple sclerosis (and spasticity). Setting: research hospitals, outpatients. Intervention:
nabiximols (2.7 mg D9-tetrahydrocannabinol and 2.5 mg cannabidiol, up to 24 sprays in 24 h) for 4–15 weeks. Comparison: placebo.
GRADE Working Group grades of evidence. High certainty: there is great confidence that the true effect lies close to that of the estimate of
the effect. Moderate certainty: there is moderate confidence in the effect estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited; the true effect
may be substantially different from the estimate of the effect. Very low certainty: there is very little confidence in the effect estimate; the
true effect is likely to be substantially different from the estimate of the effect. ADL, activities of daily living; AE, adverse event; CG,
control group; CGIC, carer global impression of change; CI, confidence interval; EQ-5D, EuroQol-5 Dimensions; IG, intervention group;
MAS, modified Ashworth scale; MSQOL-54, Multiple Sclerosis Quality of Life 54 items; NRS, numerical rating scale; OR, odds ratio;
QOL, quality of life; RCT, randomized controlled trial; SAE, serious adverse event; SF-36, 36-item Short Form Health Survey; SGIC,
subjective global impression of change. aSevere risk of bias. bInconsistency.
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9. Transcutaneous electrical nerve stimulation is sug-
gested to reduce spasticity in patients with severe
MS (weak recommendation/very low certainty evi-
dence), considering patient preferences and resource
availability.
10. It is suggested that benzodiazepines are not used
to reduce spasticity in patients with severe MS due to
insufficient evidence for efficacy and frequent ad-
verse events (weak recommendation/very low cer-
tainty evidence).
Fatigue
In total, 10/44 publications (nine trials) addressed fa-
tigue as an outcome. Five of these publications (four trials)
considered drugs (cannabinoids and 4-aminopyridine) and
five publications considered exercise (Appendices S5, S6).
Because of the limited direct evidence on the efficacy of
interventions for fatigue in this population, the TF decided
to include indirect evidence available from the National
Institute for Health and Care Excellence (NICE) guidance on
the management of MS in primary and secondary care48 and
the Cochrane review on exercise therapy for fatigue in MS.49
Recommendations.
1. D9-tetrahydrocannabinol or cannabis plant extract
(weak recommendation/low certainty evidence) or
4-aminopyridine (weak recommendation/very low cer-
tainty evidence) is suggested to treat fatigue in
patients with severe MS. Drug availability, the pres-
ence of other symptoms and possible adverse events
should be considered in treatment decision-making.
2. Exercise training is suggested to treat fatigue in pa-
tients with severe MS. This includes robot-assisted
gait training, inspiratory muscle training, upper body
endurance training and manual wheelchair propulsion
training (weak recommendation/ very low certainty
evidence). Patient preferences and the setting and
availability of the apparatus should be considered in
decision-making.
3. It is suggested that nabiximols are not used to
treat fatigue in patients with severe MS (weak
recommendation/low certainty evidence).
Additional recommendations based on indirect
evidence (weak recommendations/very low certainty
evidence).
1. It is suggested that amantadine is used to treat fatigue
in patients with severe MS.
2. Mindfulness-based training, cognitive behavioural
therapy, fatigue management programmes or other ex-
ercise training is suggested to treat fatigue in patients
with severe MS. Patient preferences and the setting
and availability of the programme should be consid-
ered in decision-making.
Pain
Seven full-text publications (six trials) addressed pain
as an outcome: five were on drugs (cannabinoids) and two
on non-pharmacological treatments (Appendices S5, S6).
Because of the limited direct evidence on the efficacy of
interventions for pain in this population, the TF decided
to include indirect evidence available from pertinent EAN
and NICE guidelines.50–52
Recommendations.
1. Any of the three different cannabinoid preparations
(D9-tetrahydrocannabinol, cannabis sativa plant ex-
tract or nabiximols) are suggested to reduce pain in
patients with severe MS (weak recommendation/low
certainty evidence). Drug availability, the presence of
FIG. 4. Efficacy of nabiximols (versus placebo) to treat spasticity: forest plots of patient and caregiver assessments.
CI, confidence interval; df, degree of freedom; IV, instrumental variable.
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other symptoms and possible adverse events should be
considered in treatment decision-making.
2. Radial shock wave therapy (weak recommendation/
low certainty evidence) or transcutaneous electrical
nerve stimulation (preferably 8-h application time;
weak recommendation/very low certainty evidence)
are suggested to reduce pain in patients with severe
MS. Patient preferences and treatment availability
should be considered in treatment decision-making.
Additional recommendations based on indirect
evidence (weak recommendations/very low certainty
evidence).
1. Gabapentin, pregabalin, amitriptyline, duloxetine or
lamotrigine is suggested to reduce pain in patients
with severe MS. The presence of other symptoms and
possible adverse events should be considered in
treatment decision-making.
2. Opioids might be considered if long-term pain treat-
ment is not an issue.
3. Carbamazepine or oxcarbazepine is suggested for pa-
tients with severe MS and trigeminal neuralgia. Sec-
ond choice drugs might be lamotrigine, gabapentin,
botulinum toxin type A, pregabalin, baclofen and
phenytoin, used either alone or as add-on therapy.
Surgery might be offered if medical treatment is not
effective or is poorly tolerated.
Bladder problems
Bladder symptoms are present in over 90% of patients
with progressive MS. Difficulty with storage control (urinary
frequency, urgency and incontinence) is the most common
symptom, caused by neurogenic detrusor overactivity. Ap-
proximately half of the patients have coexistent voiding
difficulty due to detrusorsphincter-dyssynergia.53
Six of the 44 included publications (four trials) addressed
drugs to improve urinary continence in severely affected MS
patients (Table 4). Two studies were crossover RCTs: one
compared antimuscarinics for urinary incontinence and one
desmopressin intranasal spray to placebo for nocturia. Two
studies were RCTs on cannabinoids which included urinary
symptoms as secondary outcomes. These drugs are generally
used in combination with (self-)catheterization. A range of
other drugs (e.g. new antimus-carinics, mirabegron) and
neurostimulation/ neuromodulation approaches are now
available, which need to be proved effective in this popu-
lation (Appendices S5, S6). Because of the limited direct
evidence on the efficacy of interventions for bladder symp-
toms in this population, the TF decided to include indirect
evidence available from the NICE guideline on urinary
incontinence in neurological disease.54
Recommendations.
1. Antimuscarinic drugs are suggested to improve uri-
nary continence in patients with severe MS (weak
recommendation/very low certainty evidence). The
presence of other symptoms (e.g. cognitive problems)
and possible adverse events should be considered
when deciding on the most suitable preparation, dose
and route of administration.
2. D9-tetrahydrocannabinol or cannabis extract is sug-
gested to improve urinary continence in patients
with severe MS (weak recommendation/low certainty
evidence). Drug availability, the presence of other
symptoms and possible adverse events should be
considered in decisionmaking.
3. Desmopressin intranasal spray is suggested for
nocturia in patients with severe MS (weak recom-
mendation/very low certainty evidence). The drug
should not be offered to patients with uncontrolled
hypertension, cardiovascular and/or renal diseases.
Possible adverse events should be considered in
decision-making.
4. It is suggested that nabiximols are not used to improve
urinary continence in patients with severe MS due to
insufficient evidence for efficacy (weak recommen-
dation/low certainty evidence).
Additional recommendations based on indirect
evidence (weak recommendations/very low certainty
evidence).
1. Behavioural management programmes (e.g. timed
voiding, bladder retraining or habit retraining) are
suggested to improve urinary continence in patients
with severe MS.
2. Pelvic floor muscle training – alone or in combination
with biofeedback and/or electrical stimulation of the
pelvic floor – is suggested to improve urinary conti-
nence in patients with severe MS.
3. It is suggested that patients with severe MS with
a persistent residual volume >100 ml are offered
the opportunity to learn clean intermittent self-
catheterization. If self-catheterization is not possi-
ble, a patient carer can be trained to catheterize the
patient.
4. If clean intermittent (self-)catheterization is no longer
possible, a long-term indwelling catheter (preferably
suprapubic) might be offered.
5. Patients with severe MS in whom antimuscarinic
drugs have proved to be ineffective or poorly tolerated
might be offered intradetrusor injections of botulinum
toxin A.
Multidisciplinary rehabilitation (clinical question 6)
According to Wade55 rehabilitation is a problem-solving
educational process aimed at reducing symptoms and
limitations at the level of activity and participation. Multi-
disciplinary rehabilitation encompasses different interven-
tions applied by a number of different (health) professionals,
including physiotherapists, physicians, nurses, occupational
therapists, psychologists. It is frequently delivered in reha-
bilitation clinics on an inpatient or outpatient basis and
sometimes at community centres or the patients’ home. Khan
et al.56 defined multidisciplinary (also called interdisci-
plinary) rehabilitation as ‘an inpatient, outpatient, home or
community-based coordinated intervention, delivered by
two or more disciplines in conjunction with physician con-
sultation (neurologist or rehabilitation medicine physician),
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which aims to limit patient symptoms, and enhance func-
tional independence and maximize participation, as defined
by ICF [International Classification of Functioning, Dis-
ability and Health].’57
Eleven publications were found reporting on nine trials
(eight RCTs and one controlled clinical trial) that differed
in terms of setting, intervention (components, duration and
intensity), outcomes and length of follow-up. Therefore it
was not possible to perform meta-analyses, and results were
summarized descriptively (Appendices S5, S6).
Recommendations.
1. It is suggested that multidisciplinary rehabilitation is
offered to patients with severe MS (weak recom-
mendation/very low or low certainty evidence).
2. Multidisciplinary rehabilitation might be offered
either as inpatient, outpatient or home-based rehabil-
itation or as a combination (weak recommendation/
very low or low certainty evidence). Patients’ pref-
erence and other circumstances (transport, situation
at home and resources) should be taken into account
when deciding on the setting.
Interventions for caregivers (clinical questions
7 and 8)
Two clinical questions concerned interventions for care-
givers, in terms of structured education and training pro-
grammes on caregiving, and of structured, practical and/or
emotional support programmes (Appendix S2). One RCT58
comparing a 2-year, community-based, comprehensive care
programme for MS patients and caregiver units to usual care
were included. The trial (also included in clinical question 6
on multidisciplinary rehabilitation) addressed both clinical
questions 7 and 8, as the programme included education
as well as practical and emotional support for caregivers
(Appendix S5).
Recommendations.
1. It is suggested that caregivers of patients with severe
MS are offered education and training programmes on
caregiving (weak recommendation/ very low certainty
evidence). Caregivers’ preferences and habits should
be taken into account when deciding on the setting
of the programme, e.g. hospital based, home based or
online.
2. It is suggested that caregivers of patients with severe
MS are offered practical and emotional support (weak
recommendation/very low certainty evidence). Care-
givers’ preferences and habits should be taken into
account when deciding on the setting of the support
programme.
Interventions for HPs (clinical questions 9 and 10)
Finally, two clinical questions concerned education and
training for HPs: one concerned training in PC/ specialist PC
for MS HPs, and one training in MS for PC HPs (Appendix
S2). No evidence was found regarding the effectiveness of
any of these training programmes (of 37 records screened,
two were assessed as full text and excluded from the final
selection; Appendix S5). There is increasing discussion of
the need for close collaboration between PC and neurology,
and for neurologists to receive training in basic PC princi-
ples.59–62 It has been recommended that neurologists should
have familiarity and comfort with communicating bad news,
engaging in end-of-life conversations and ACP, caregiver
assessment and other PC skills. On the other hand, PC teams
may also need specialized training for managing MS patients.
The required competences can be achieved through enhanced
joint training within the two specialties.62 Despite efforts
to improve the PC training of neurology residents,63 there is
no evidence available as to its use or effectiveness and rec-
ommendations can only be made by consensus using the
evidence from the literature.10
Good practice statements.
1. It is suggested that the principles of PC are included in
the training and continuing education of neurologists
and other HPs involved in MS care.
2. It is suggested that the principles of the management
of MS patients are included within the training and
continuing education of specialist PC professionals.
Discussion
Recognizing significant variation in the PC of patients with
severe MS across Europe, the EAN assembled a TF to
summarize the existing evidence and develop a clinical
practice guideline. To ensure client involvement the TF in-
cluded a person with MS who participated in all aspects of the
development of the guideline; in addition, MS patients and
caregivers were involved via an international online survey
and focus group meetings in the formulation of the 10 clinical
questions.13
For four clinical questions (1, 2, 5 and 6) the TF produced
34 recommendations (one of which was a strong recom-
mendation) and one good practice statement. For interven-
tions for caregivers (clinical questions 7 and 8) only one
study was found. No research evidence was found for four
clinical questions: ACP (3), discuss with HPs the wish to
hasten death (4), and interventions for HPs (9, 10). For these
four clinical questions, the TF produced six good practice
statements. Thus, there is currently a knowledge gap on
many questions in this population, and on several outcomes
considered as important by stakeholders (Fig. 1).
Two pertinent studies have been published since the search
was closed. One was a Cochrane review on PC in MS pa-
tients, which included the same RCTs as in our IPDMA.64 It
should be noted, however, that in this systematic review pain
and sleeping problems were considered as PC adverse events
and the pre-specified secondary outcome measures included
relapse-free survival, progression-free survival, neuropsy-
chological assessment and the EDSS.64 The other study was
a pragmatic RCT from the UK, which demonstrated that a
standing frame programme significantly increased motor
function in people with severe MS and was cost-effective in
comparison to standard care.65
The limited evidence on PC in MS (and in other neuro-
logical conditions) contrasts with the situation in oncology.10
The TF agreed on the formulation of good practice statements
(instead of abstaining from any recommendation) in response
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to clinical questions where evidence was lacking. This was
the case for ACP where, besides the all-important differ-
ences in clinical features, commonalities may exist in the
psychosocial and spiritual needs across patient popula-
tions. Whilst emphasizing the need to produce evidence in
MS, consensus documents on ACP and interventions cur-
rently available for other conditions can inspire MS cli-
nicians to have effective conversations with their patients
and patient significant others and stimulate research in this
area.37,66,67
Conclusion
This clinical practice guideline provides evidence-based
recommendations of PC in severely affected MS patients.
Areas that currently lack evidence of efficacy include ACP,
the management of symptoms such as fatigue and mood
problems in this population, and interventions for caregivers
and HPs. Further research on the integration of PC and MS
care is needed, including consideration of the various models
of PC provision.
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